Research from Italy indicates that terminology used in validated questionnaires for patient-reported outcomes should account for the social and cultural contexts of the countries involved.
In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.
Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.